New insider activity at Edwards Lifesciences ( (EW) ) has taken place on August 25, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daveen Chopra, a key figure in the CVP and TMTT divisions, has recently sold 2,500 shares of Edwards Lifesciences stock, amounting to a total transaction value of $204,850.
Recent Updates on EW stock
Recent updates from Edwards Lifesciences Corp. highlight ongoing clinical trials that could impact their stock performance. The TRISCEND II Pivotal Trial and the 2019-06 TRISCEND Study focus on the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement system, aiming to improve outcomes for patients with tricuspid regurgitation. Positive results could enhance their market position in cardiovascular devices. The ENCIRCLE Trial evaluates the SAPIEN M3 System for mitral regurgitation, addressing a critical need for alternative treatments, potentially boosting investor sentiment. The SAPIEN X4 study for aortic stenosis and the ALT-FLOW II Trial for heart failure also underscore Edwards’ commitment to innovation in heart valve technologies, which may reinforce investor confidence and influence competitive dynamics in the medical device industry.
Spark’s Take on EW Stock
According to Spark, TipRanks’ AI Analyst, EW is a Outperform.
Edwards Lifesciences’ strong earnings call performance and robust financial health are the primary drivers of its stock score. The company’s positive sales growth and increased guidance highlight its growth potential. However, the high P/E ratio and cash flow challenges slightly temper the overall score.
To see Spark’s full report on EW stock, click here.
More about Edwards Lifesciences
YTD Price Performance: 12.73%
Average Trading Volume: 4,257,345
Technical Sentiment Signal: Buy
Current Market Cap: $48.04B